As of 1:30 PM on the 16th, SK is trading at 237,000 won, the same price as the previous day. The trading volume is 280,476 shares, which is 42.29% of the previous day's volume. SK is known as the holding company of the SK Group.

On July 15, analysts Yang Ji-hwan and Lee Ji-soo from Daishin Securities stated, "Despite the increase in subsidiary equity value due to the listing of SK Biopharm, the stock price adjustment phase continues. This is presumed to be due to the reduced investment merit in SK following SK Biopharm's listing. After the sale of CGH shares, decisions such as the repurchase of treasury shares in the second half of 2019 to enhance shareholder value, along with additional CGH share sales in 2020 and investment recovery through SK Biopharm's listing, increase the likelihood of dividend expansion to stabilize stock prices and enhance shareholder value. In particular, as SK Biopharm recorded a market capitalization far exceeding expectations, there is a possibility of recovering investment funds through future share sales." They set SK's target price at 400,000 won.

Over the past five days, individual investors have net purchased 138,958 shares of SK, while foreigners and institutions have net purchased 45,343 shares and net sold 195,478 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing